11 Jan 2019 Research
Lymphoma: Understanding relapse and treatment resistance
What is this research looking at?
Our immune system is remarkable. It is made up of many different types of immune cells that work together to protect the body from infection by pathogens such as bacteria, viruses and parasites.
We are investigating what happens when a certain type of cell in the immune system, known as B cells, starts growing out of control and develops into blood cancers such as leukaemia, lymphoma and myeloma.
We want to know what happens when B cells mature normally from precursor cells in the bone marrow and discover what has gone wrong when they turn into cancer cells instead.
Considerable success has been achieved in the treatment of lymphoma. However, a significant unmet need remains: roughly 40% of patients either do not respond to treatment or the condition recurs after treatment. Currently, our ability to predict which patients will fail treatment is poor.
By taking a detailed look at B cells as they develop and specialise, we can spot small groups of dangerous cells that are particularly likely to turn into cancer and identify the genetic faults that drive B cells to grow out of control.
We are using our knowledge to create new models for the development of B cells and blood cancers in the lab, so we can find new ways to treat or even prevent these deadly diseases.
Our research uses a model of lymphoma to test the response to treatments and development of resistance. A main advantage of the model is that we can interrogate these questions on a well-defined scenario and can perform iterative tests and predictions. Further, the model generated in this project will allow initial testing of novel treatments.
What could this mean for people with leukaemia?
This research could inform the medical decision of when to use combination and novel therapies for patients with a higher probability of developing resistance to standard treatment, alongside bringing safer treatments to patients.
Official project title: Development of a model system to study diffuse large B cell lymphoma clonal evolution
Related posts
2 August 2023
Friends and family of Leicestershire woman who died from rare cancer campaign for more research and awareness
The family of a Leicestershire woman who died in July 2022, on the day of her leukaemia diagnosis, has raised over £17,000 in her memory to support Leukaemia UK. On…
4 July 2022
Cancer charities unite in encouraging the Government to address crucial issues as part of their “War on Cancer”
In collaboration with our partners and as part of the One Cancer Voice group, Cancer 52 and Blood Cancer Alliance, we have called on the Government to take account of a wide range of recommendations as they finalise the 10-Year Cancer Plan to be announced later this year.
16 November 2021
Charities call on NHS to treat blood cancer equally in decision-making
The Blood Cancer Alliance undertook an evidence review to inform a new report exploring the unmet needs of people with blood cancer across the UK.
22 May 2023
Can the unique differences between stem cells tell us how well CML treatment will work?
What if we could predict how chronic myeloid leukaemia (CML) patients will respond to treatment? Could the unique signatures of CML stem cells hold the key to personalising treatment for…